// App-Quantinova.ai

: Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study

Researchers

Presenter

  • Konstantinos Kostikas

Principal Investigators

  • Alexander J. Mackay

  • Claus F. Vogelmeier

  • Stefan-Marian Frent

  • Pascal Pfister

  • Pritam Gupta

  • Donald Banerji

  • Francesco Patalano

  • Jadwiga A. Wedzicha

Medical Centers

  • Novartis AG, Basel, Switzerland

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Pulmonary and Critical Care Medicine, Philipps–Universität Marburg, Marburg, Germany

  • Medical Semiotics, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Respiratory Clinical Science Section National Heart and Lung Institute, Imperial College London, London, United Kingdom, London, United Kingdom

Locations

  • Switzerland

  • United Kingdom

  • Germany

  • Romania

  • India

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved